Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia

Affiliations

¹ Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, India.
² Tata Translational Cancer Research Centre, Kolkata, India; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M20 4GJ, UK. Electronic address: v.saha@manchester.ac.uk.

Comment

Niharendu Ghara et al. Lancet Haematol. 2023 Jun.

. 2023 Jun;10(6):e391-e393.

doi: 10.1016/S2352-3026(23)00091-1. Epub 2023 May 8.

¹ Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, India.
² Tata Translational Cancer Research Centre, Kolkata, India; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M20 4GJ, UK. Electronic address: v.saha@manchester.ac.uk.

No abstract available

Conflict of interest statement

VS is supported by a centre grant from the Tata Consultancy Services Foundation. NG declares no competing interests.

Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Sato A, et al. Lancet Haematol. 2023 Jun;10(6):e419-e432. doi: 10.1016/S2352-3026(23)00072-8. Epub 2023 May 8. Lancet Haematol. 2023. PMID: 37167992 Clinical Trial.